Intensified tuberculosis treatment with or without aspirin to reduce mortality from tuberculous meningitis in HIV-infected and uninfected patients
Tuberculous meningitis (TBM) is an infectious disease caused by a bacterium called Mycobacterium tuberculosis or Koch’s bacillus. It is the most serious form of tuberculosis (TB), affecting the brain and spinal cord, with around 164,000 new cases each year worldwide. In people living with HIV (PLHIV), mortality is as high as 50% despite treatment, and neurological sequelae are common.
INTENSE-TBM is a multicentre, randomised, controlled, superiority Phase III clinical trial in a 2 x 2 factorial design taking place in South Africa, Côte d’Ivoire, Madagascar and Uganda.
The main objective is to evaluate the effectiveness of two interventions aimed at reducing mortality due to tuberculous meningitis (TBM) in adults with or without HIV co-infection, in sub-Saharan Africa :
• Intensified” treatment for BTM, compared with the WHO standard treatment for BTM.
• Aspirin, compared with no aspirin (placebo).
Vanessa Machault
vanessa.machault@u-bordeaux.fr
Discover our activities
in research and teaching
of Bordeaux's university sites.
. University of Bordeaux
. Institute of Public Health, Epidemiology and Development (Isped)
. Bordeaux Population Health Research Center (BPH)
. Bordeaux School of Economics (BSE)
. Sciences Po Bordeaux
Click on the names of the countries where we operate below the map!
